Modulation by Insulin of the Co-Localized LDL Receptor in Normal and Type-I Diabetic Subjects
Shilpa Suneja, Gopalakrishnan Ramakrishnan, Nikhil Tandon, N.C. Chandra
DOI: 10.4236/ijcm.2011.23038   PDF   HTML     4,860 Downloads   7,819 Views   Citations


Ongoing insulin therapy maintains LDL receptors at highly expressed state in Type-1 diabetic people; yet Type-1 diabetics are liable of having higher plasma LDL level. This disparity has raised doubt on the probability of existence of functionally active LDL receptor in such people. Confocal microscopy and immunoprecipitation have made it evident that a portion of insulin and LDL receptors remain together in a co-localized mode, which only gets freed in presence of insulin. The findings of this study have shown that insulin therapy protects Type-1 diabetic people from the pathogenesis of atherosclerosis by decimating the inactivity of the co-localized LDL receptors in addition to its regular effect of having increased glucose tolerance. The existence of co-localized state of these two receptors and their dependence on insulin for independent activity has, at least, presented a reason for developing hypercholesterolemia and advanced coronary atherosclerotic lesion in chronic Type-1 diabetic subjects.

Share and Cite:

S. Suneja, G. Ramakrishnan, N. Tandon and N. Chandra, "Modulation by Insulin of the Co-Localized LDL Receptor in Normal and Type-I Diabetic Subjects," International Journal of Clinical Medicine, Vol. 2 No. 3, 2011, pp. 231-245. doi: 10.4236/ijcm.2011.23038.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] E. I. Sokolov, “Diabetes Mellitus and Atherosclerosis,” M. Nauka, 1996, p. 404.
[2] P. N. Bodiar, G. M. Denish and O. R. Panasyukova, “Endocrinol Problems,” Vol. 3, 1984, pp. 19-24.
[3] A. Araszkiewicz, D. Zozulińska, M. Trepińska, et al., “Inflammatory Markers as Risk Factors for Microangiopathy in Type 1 Diabetic Patients on Functional Intensive Insulin Therapy from the Onset of the Disease,” Diabetes Research and Clinical Practice, Vol. 74, No. 2, 2006, pp. S43-S40.
[4] S. G. Kozlov and A. A. Lyakishev, “Dyslipoprotenemias and Their Treatment in Patients with Non-Insulin Dependent Diabetes Mellitus,” Cardiology, Vol. 8, 1999, pp. 59-64.
[5] G. Assmann and H. Schulte, “The Prospective Cardiovascular Munster (PROCAM) Study: Prevelance of Hyperlipidemia in Persons with Hypertension and/or Diabetes Mellitus and the Relationship to Coronary Heart Disease,” American Heart Journal, Vol. 116, 1988, pp. 1713-1724.
[6] M Laakso, “Epidemiology of Diabetic Dyslipidemia,” Diabetes Reviews, Vol. 3, 1955, pp. 408-422.
[7] M. Laakso, E. Voutilainen, H. Sarlund, et al., “Serum lipids and Lipoproteins in Middle-Aged Non-Insulin Dependent Diabetics,” Atherosclerosis,Vol. 56, 1985, pp. 271-281.
[8] K. Py?r?l?, M. Laakso and M. Uusitupa, “Diabetes and Atherosclerosis: an Epidemiological View,” Diabetes/ Metabolism Reviews, Vol. 3, 1987, pp. 463-524.
[9] G. Steiner, “The Dyslipoproteinemias of Diabetes,” Atherosclerosis, Vol. 110, 1994, pp. 27-33.
[10] M. R. Taskinen, “Quantitative and Qualitative Lipoprotein Abnormalities in Diabetes Mellitus,” Diabetes, Vol. 41, No. S2, 1992, pp. 12-17.
[11] S. M. Haffner, M. P. Stern, H. P. Haruda, et al., “Cardiovascular Risk Factors in Confirmed Prediabetic Individuals: Does the Clock for Coronary Heart Disease Start Ticking before the Onset of Clinical Diabetes?,” The Journal of the American Medical Association, Vol. 263, 1990, pp. 2893-2898.
[12] M. Laakso, T. Ronnemaa, K. Py?r?l?, et al., “Atherosclerosis Vascular Disease and Its Risk Factors on Non-Insulin Dependent Diabetic and Non-Diabetic Subjects in Finland,” Diabetes Care, Vol. 11, 1988, pp. 449-463.
[13] J. Stamler, O. Vaccaro, J. D. Neaton, et al., ”The Multiple Risk Factor Intervention Trial Research Group. Diabetes and Other Risk Factors on Coronary Heart Disease and Mortality among Middle-Aged Diabetic Men: A General Population Study,” Diabetes Care, Vol. 16, 1993, pp. 434-444.
[14] M. P. Stern, J. K. Patterson, S. M. Haffner, et al., “Lack of Awareness and Treatment of Hyperlipidemia in Type-2 Diabetes in a Community Survey,” The Journal of the American Medical Association, Vol. 262, 1989, pp. 360-364.
[15] L. P. Krall, “Clinical Evaluation of Prognosis,” In: A. Marble, P. White, R. F. Bradley and L. P. Krall, Eds., Joslin’s Diabetes Mellitus, Lea and Febiger, Philadelphia, 1973, pp. 211- 254.
[16] K. Kornerup, B. G. Nordestgaard, B. Feldt-Rasmussen, et al., “Increased Transvascular Low Density Lipoprotein Transport in Insulin Dependent Diabetes: A Mechanistic Model for Development of Atherosclerosis,” Atherosclerosis, Vol. 170, No. 1, 2003, pp. 163-168.
[17] D. P. Wade, B. L. Knight and A. K. Soutar, “Regulation of Low-Density-Lipoprotein-Receptor mRNA by Insulin in Human Hepatoma HepG2 Cells,” European Journal of Biochemistry, Vol. 181, No. 3, 1989, pp. 727-731.
[18] G. Ramakrishnan and N. C. Chandra, “Estradiol Regulates Insulin Dependent Stimulation of LDL-Receptor Expression in HepG2 Cells,” Indian Journal of Clinical Biochemistry, Vol. 21, No. 1, pp. 8-14.
[19] M. S. Brown and J. L. Goldstein, “A Receptor-Mediated Pathway for Cholesterol Homeostasis,” Science, Vol. 232, No. 4746, 1986, pp. 34-47.
[20] S. Swami, C. Sztalryd and F. B. Kraemer, “Effects of Streptozotocin-Induced Diabetes on Low Density Lipoprotein Receptor Expression in Rat Adipose Tissue,” Journal of Lipid Research, Vol. 37, 1996, pp. 229-236.
[21] L. Duvillard, F. Galland, E. Florentin, et al., “Cell surface Expression of LDL Receptor is Decreased in Type-2 Diabetic Patients and is Normalized by Insulin Therapy,” Diabetes Care, Vol. 26, No. 5, 2003, pp. 1540-1544.
[22] R. J. Havel, H. A. Eder and J. H. Bragdon, “The Distribution and Chemical Composition of Ultracentrifugally Separated Lipoprotein in Human Serum,” Journal of Clinical Investigation, Vol. 34, No. 9, 1955, pp. 1345-1353.
[23] G. Ramakrishnan, A. Rana, C. Das and N. C. Chandra, “Study of Low-Density Lipoprotein Receptor Regulation by Oral (Steroid) Contraceptives: Desogestrel, Levonor- gestrel and Ethinyl Estradiol in JEG-3 Cell Line and Placental Tissue,” Contraception, Vol. 76, 2007, pp. 297-305.
[24] M. M. Bradford, “A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding,” Analytical Biochemistry, Vol. 72, 1976, pp. 248-254.
[25] E. B. Smith and R. S. Slater, “Relationship between Low Density Lipoproteins in Aortic Intima and Serum Lipid Levels,” Lancet, Vol. 1, 1972, pp. 463-469.
[26] D. C. Schwenke and T. E. Carew, “Initiation of Atherosclerotic Lesions in Cholesterol-Fed Rabbits, II: Selective Retention of LDL vs Selective Increases in LDL Permeability in Susceptible Sites of Arteries,” Arteriosclerosis, Vol. 9, 1989, pp. 908-918.
[27] M. Cybulsky and M. Gimbrone, “Endothelial Expression of a Mononuclear Adhesion Molecule during Atherogenesis,” Science, Vol. 251, 1991, pp. 788-791.
[28] K. D. O’Brian, M. D. Allen, T. O. McDonald, et al., “Vascular Cell Adhesion Molecule-1 is Expressed in Human Coronary Atherosclerotic Plaques: Implications for the Mode of Progression of Advanced Coronary Atherosclerosis,” Journal Clinical Investigation, Vol. 92, 1993, pp. 945-951.
[29] M. Richardson, S. Hadcock, M. DeReske, et al., “Increased Expression in Vivo of VCAM-1 and E-selectin by the Aortic Endothelium of Normolipidemic and Hyperlipidemic Rabbits,” Arteriosclerosis, Thrombosis and Vascular Biology, Vol. 14, 1994, pp. 760-769.
[30] R. G. Gerrity, “The Role of the Monocyte in Atherogenesis, I: Transition of Blood-Borne Monocytes into Foam Cells in Fatty Lesions,” American Journal of Pathology, Vol. 103, 1981, pp. 181-190.
[31] R. Ross, “Atherosclerosis is an Inflammatory Disease”. American Heart Journal, Vol. 138, 1999, pp. S419-S420.
[32] M. Navab, J. A. Berliner, A. D. Watson, et al., “The Yin and Yang of Oxidation in the Development of the Fatty Streak. A Review Based on the George Lyman Duff Memorial Lecture,” Arteriosclerosis, Thrombosis and Vascular Biology, Vol. 16, No. 7, 1994, pp. 831-842.
[33] P. M. Henson and D. W. H. Riches, “Modulation of Macrophage Maturation by Cytokines and Lipid Mediators: A Potential Role in Resolution of Pulmonary Inflammation,” Annals of the New York Academy of Sciences, Vol. 725, 2006, pp. 298-308.
[34] Y. Liu, L. M. Hulten and O. Wiklund, “Macrophages Isolated from Human Atherosclerotic Plaques Produce IL-8, and Oxysterols may Have a Regulatory Function for IL-8 Production,” Arteriosclerosis, Thrombosis and Vascular Biology, Vol. 17, 1997, pp. 317-323.
[35] J. A. Maries, S. Dahesh, J. Haynes, et al., “Protein-Pro- tein Interaction Affinity Plays a Crucial Role in Controlling the sho1p-Mediated Signal Transduction Pathway in Yeast,” Molecular Cell, Vol. 14, 2004, pp. 813-823.
[36] Y. C. Chen, H. C. Chen and J. M. Yang, “A 3D-Domain Annoted Protein-Protein Interaction Database,” Genome Informatics, Vol. 17, No. 2, 2006, pp. 206-215.

Copyright © 2021 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.